Developer docs
API playgroundTry for free, no card

Search company profiles

Wuhan General Group

Full company profile

uuid0006wol

Namestring
Wuhan General Group
Legal namestring
Wuhan General Group
Websiteurl
m2bio.co
Company typeenum
Public
Founded yearint
1988
Descriptiontext

Wuhan General Group is a publicly traded nutraceutical biotechnology company (OTCPINK: WUHN) focused on the research and development of alternative plant-based cannabinoids and psilocybin for medical applications. Founded in 1988 and headquartered in Cape Town, South Africa, the company operates with a small team of 11-50 employees. The company's website (m2bio.co) suggests operational alignment with the M2Bio brand, indicating a pivot from its original corporate identity toward the biotechnology and cannabinoid research sector. Its public listing on OTC Markets — rather than a major exchange — is consistent with its micro-cap status and limited scale.

The company has pursued growth through targeted acquisitions, including MJ MedTech in 2019 and JDAX in 2023, both for undisclosed amounts, signaling a roll-up strategy in the medical cannabis and psilocybin research space. In December 2020, it secured a $450,000 funding round led by ThreeD Capital, a specialized investment firm. Leadership comprises CEO Michael Sachar and CIO/CXO Esmarilda Dankaert. No specific product portfolio, pricing model, customer base, or revenue figures are disclosed in available sources; comparative financial analyses consistently report N/A across all financial metrics. The company's revenue model, distribution channels, and customer segmentation approach remain undisclosed.

The lack of disclosed financials, minimal headcount, OTC Markets listing, and absence of identified customers or marketing channels indicate a sub-scale operation likely in early commercial or pre-commercial stages. The company's competitive positioning in the highly regulated and competitive cannabinoid and psilocybin research space is not well-evidenced by the available data, and its ability to scale remains unclear without access to revenue, product pipeline, or partnership disclosures.

Short descriptiontext

Wuhan General Group is a publicly traded (OTCPINK: WUHN) nutraceutical biotechnology company focused on alternative plant-based cannabinoid and psilocybin medical research, headquartered in Cape Town, South Africa, with 11-50 employees and operations dating to 1988.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCape Town, South Africa
HQ citystring
Cape Town
HQ countrystring
South Africa
HQ regionstring
Africa
Markets served

Serves global market

Keyword5 values
plant-based cannabinoids, psilocybin medical research, nutraceutical biotechnology, alternative therapeutics, cannabis biotech research
Industry3 codes
1CBD/Hemp Wellness & Supplements Retail
CodeCRANAHACPrimaryYes
2CBD/Hemp Topicals & Beauty Retail
CodeCRANAHABPrimaryNo
3Hemp & CBD Product Wholesale Distribution
CodeCRAOAIAGPrimaryNo
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Nutraceutical Biotechnology
Social media profiles3 records
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Wuhan General Group is a publicly traded nutraceutical biotechnology company that develops alternative plant-based cannabinoids and conducts psilocybin medical research. Its commercial activity centers on researching, developing, and (per its stated focus) commercializing plant-derived cannabinoid alternatives and psilocybin-based therapeutic candidates. The company has expanded through acquisitions of MJ MedTech (2019) and JDAX (2023).

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Alternative plant-based cannabinoid compounds
CategoryNutraceutical Biotechnology
2Psilocybin medical research programs
CategoryBiotechnology Research
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers4 records
1Compass Pathways
TypeDirect peer
Description

Pure-play psilocybin therapy developer with COMP360 in late-stage clinical trials for treatment-resistant depression. Closest large-scale psilocybin peer for a company claiming psilocybin medical research.

2Charlotte's Web Holdings
TypeDirect peer
Description

Public CBD/hemp wellness company selling plant-derived cannabinoid tinctures, topicals, and supplements. Most directly comparable to Wuhan General Group's CBD/hemp wellness focus and public micro-cap profile.

3MindMed (Mind Medicine)
TypeDirect peer
Description

Clinical-stage psychedelic medicine biotech developing psilocybin and MDMA-based therapies. Directly comparable on the psilocybin research axis of Wuhan General Group's stated strategy.

4atai Life Sciences
Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wuhan General Group

Nutraceutical Biotechnologym2bio.co

Wuhan General Group is a publicly traded (OTCPINK: WUHN) nutraceutical biotechnology company focused on alternative plant-based cannabinoid and psilocybin medical research, headquartered in Cape Town, South Africa, with 11-50 employees and operations dating to 1988.

What Wuhan General Group does

Wuhan General Group is a publicly traded nutraceutical biotechnology company (OTCPINK: WUHN) focused on the research and development of alternative plant-based cannabinoids and psilocybin for medical applications. Founded in 1988 and headquartered in Cape Town, South Africa, the company operates with a small team of 11-50 employees. The company's website (m2bio.co) suggests operational alignment with the M2Bio brand, indicating a pivot from its original corporate identity toward the biotechnology and cannabinoid research sector. Its public listing on OTC Markets — rather than a major exchange — is consistent with its micro-cap status and limited scale.

The company has pursued growth through targeted acquisitions, including MJ MedTech in 2019 and JDAX in 2023, both for undisclosed amounts, signaling a roll-up strategy in the medical cannabis and psilocybin research space. In December 2020, it secured a $450,000 funding round led by ThreeD Capital, a specialized investment firm. Leadership comprises CEO Michael Sachar and CIO/CXO Esmarilda Dankaert. No specific product portfolio, pricing model, customer base, or revenue figures are disclosed in available sources; comparative financial analyses consistently report N/A across all financial metrics. The company's revenue model, distribution channels, and customer segmentation approach remain undisclosed.

The lack of disclosed financials, minimal headcount, OTC Markets listing, and absence of identified customers or marketing channels indicate a sub-scale operation likely in early commercial or pre-commercial stages. The company's competitive positioning in the highly regulated and competitive cannabinoid and psilocybin research space is not well-evidenced by the available data, and its ability to scale remains unclear without access to revenue, product pipeline, or partnership disclosures.

Wuhan General Group firmographics

Firmographics
Name
Wuhan General Group
Legal name
Wuhan General Group
Website
https://m2bio.co
Company type
Public
Founded year
1988
Operating status
Operating
Headcount range
11–50 employees
Short description
Wuhan General Group is a publicly traded (OTCPINK: WUHN) nutraceutical biotechnology company focused on alternative plant-based cannabinoid and psilocybin medical research, headquartered in Cape Town, South Africa, with 11-50 employees and operations dating to 1988.
Ownership category
akta.pro rank

Wuhan General Group industry classification

Industry
Product category
Nutraceutical Biotechnology
NAICS
Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
CBD/Hemp Wellness & Supplements Retail (CRANAHAC)
akta.pro secondary industries
CBD/Hemp Topicals & Beauty Retail (CRANAHAB), Hemp & CBD Product Wholesale Distribution (CRAOAIAG)

Keywords

  • Plant-based cannabinoids
  • Psilocybin medical research
  • Nutraceutical biotechnology
  • Alternative therapeutics
  • Cannabis biotech research

Where Wuhan General Group is headquartered

Location

Headquarters

HQ city
Cape Town
HQ country
South Africa
HQ region
Africa

Markets served

Wuhan General Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Wuhan General Group product offering

Product offering

Core offering

Wuhan General Group is a publicly traded nutraceutical biotechnology company that develops alternative plant-based cannabinoids and conducts psilocybin medical research. Its commercial activity centers on researching, developing, and (per its stated focus) commercializing plant-derived cannabinoid alternatives and psilocybin-based therapeutic candidates. The company has expanded through acquisitions of MJ MedTech (2019) and JDAX (2023).

Differentiator

Problem solved

Functional benefit

Products and services

  • Alternative plant-based cannabinoid compounds
  • Psilocybin medical research programs

Companies that use Wuhan General Group

Customer profile

Segments1 record

Ideal customer profiles1 record

Wuhan General Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Wuhan General Group partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves4 records

Expansion highlights3 records

Wuhan General Group competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Pure-play psilocybin therapy developer with COMP360 in late-stage clinical trials for treatment-resistant depression. Closest large-scale psilocybin peer for a company claiming psilocybin medical research.
  • Charlotte's Web Holdings: Public CBD/hemp wellness company selling plant-derived cannabinoid tinctures, topicals, and supplements. Most directly comparable to Wuhan General Group's CBD/hemp wellness focus and public micro-cap profile.
  • MindMed (Mind Medicine): Clinical-stage psychedelic medicine biotech developing psilocybin and MDMA-based therapies. Directly comparable on the psilocybin research axis of Wuhan General Group's stated strategy.

Peers

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Wuhan General Group social profiles

Digital presence

Wuhan General Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wuhan General Group leadership team

Management profile

Number of profiles

Profiles2 records

Wuhan General Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wuhan General Group M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wuhan General Group

What does Wuhan General Group do?

Wuhan General Group is a publicly traded nutraceutical biotechnology company that develops alternative plant-based cannabinoids and conducts psilocybin medical research. Its commercial activity centers on researching, developing, and (per its stated focus) commercializing plant-derived cannabinoid alternatives and psilocybin-based therapeutic candidates. The company has expanded through acquisitions of MJ MedTech (2019) and JDAX (2023).

Is Wuhan General Group a public or private company?

Wuhan General Group is a public company. It is classified as public and is currently operating.

When was Wuhan General Group founded?

Wuhan General Group was founded in 1988. It employs 11 to 50 people.

Where is Wuhan General Group based?

Wuhan General Group is headquartered in Cape Town, South Africa, in the Africa region.

Who are Wuhan General Group's main competitors?

Direct peers on record are Compass Pathways, Charlotte's Web Holdings and MindMed (Mind Medicine). atai Life Sciences is listed as a peer.

Does Wuhan General Group have an API?

No public API is recorded for Wuhan General Group.

What industry is Wuhan General Group in?

Wuhan General Group's product category is Nutraceutical Biotechnology. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAHAB, CBD/Hemp Topicals & Beauty Retail. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldCritical Analysis: Trimble (NASDAQ:TRMB) versus Wuhan General Group (OTCMKTS:WUHN)This article presents a comparative analysis of two industrials companies—Trimble and Wuhan General Group—across ten financial metrics including revenue, earnings, valuation, risk, and analyst ratings. Trimble outperforms Wuhan General Group on nine of the ten factors examined, with Trimble reporting $3.59 billion in gross revenue, $1.75 earnings per share, and a consensus target price of $92.78 suggesting 37.75% upside potential. Wuhan General Group shows N/A across most financial metrics and has no analyst coverage, while Trimble holds a rating score of 2.83 with a beta of 1.53 indicating higher volatility than the S&P 500.Defense WorldCritical Comparison: DXP Enterprises (NASDAQ:DXPE) & Wuhan General Group (OTCMKTS:WUHN)This article presents a comparative financial analysis of DXP Enterprises (NASDAQ:DXPE) and Wuhan General Group (OTCMKTS:WUHN), two industrial companies, evaluating them across 11 factors including institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation, and risk. DXP Enterprises outperforms Wuhan General Group on 10 of the 11 comparison metrics, with DXP showing $2.02 billion in revenue, $88.68 million net income, and analyst ratings of 2 buy and 1 strong buy recommendations, compared to Wuhan General Group showing no available financial data and zero analyst ratings.Defense WorldHead-To-Head Review: Xometry (NASDAQ:XMTR) versus Wuhan General Group (OTCMKTS:WUHN)This article presents a head-to-head financial comparison between Xometry and Wuhan General Group across multiple metrics including institutional ownership, valuation, earnings, analyst recommendations, and profitability. Xometry outperforms Wuhan General Group on 6 of 10 comparison factors, with a consensus target price of $62.00 suggesting 25.51% potential upside. The analysis shows Xometry has stronger analyst coverage with a 2.36 rating score versus no analyst coverage for Wuhan General Group, though both companies face challenges with negative margins.Defense WorldAscent Industries (NASDAQ:ACNT) versus Wuhan General Group (OTCMKTS:WUHN) Head-To-Head SurveyThis article presents a side-by-side financial comparison of two industrials companies: Ascent Industries (NASDAQ:ACNT) and Wuhan General Group (OTCMKTS:WUHN). Ascent Industries demonstrates stronger financial metrics with $74.94 million in revenue and positive earnings, while Wuhan General Group shows N/A across all financial categories. The comparison also covers institutional and insider ownership, analyst ratings, profitability metrics, and stock volatility, with Ascent Industries receiving a 2.00 rating score from one hold recommendation.GlobeNewswireMRES: M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Exhibiting Numerous Medicinal Health BenefitsM2Bio Sciences announced a line of purple, white, and green teas from Kenya, with purple tea having 135 times more antioxidants than black tea. The teas are available online and through select retailers starting in Q1 2024. CEO Jeff Robinson will visit Kenya from July 24-31 to strengthen partnerships.PR NewswireMRES: M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAXM2Bio Sciences has signed a letter of intent to acquire JDAX, a South African cryptocurrency exchange, with the transaction expected to close by July 31, 2023. The acquisition aims to leverage JDAX's blockchain technology to tokenize research projects and issue NFTs representing fractional ownership of bioactive compounds discovered through M2Bio's AI-driven drug discovery programs.GlobeNewswireThreeD Capital To Make Largest Investment Into Psychedelics Industry With US$450,000 Investment Into Wuhan General Group (China) Inc.ThreeD Capital announced a US$450,000 investment in Wuhan General Group (China) Inc., a biotech focused on psilocybin research. The company will acquire 1.5 million units at $0.30 each, with warrants expiring three years later. The closing date is set for January 31, 2021.NasdaqWuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional FoodsWuhan General Group signed a letter of intent with Jugular to collaborate on developing CBD functional foods, which is expected to be formalized by September 30, 2020. The partnership aims to create marketable health-focused products such as immune boosters, energy shots, and relaxation shots using African medicinal ingredients, under the Dr. AnnaRx brand.GlobeNewswireSDT Holdings Improve Transparency with Information & Disclosure Statement FilingSDT Holdings, Inc. filed its Information and Disclosure Statement with OTC Markets, including financials for 2016-2017 and Q1 2018, aiming for Current Pink status. The company also filed a Nevada amendment to change its name from Wuhan General Group (China), Inc. to SDT Holdings, Inc., and is seeking a new ticker symbol.GlobeNewswireThe Company announces that it has finalized the merger withSDT Holdings finalized a reverse takeover merger with Wuhan General Group (China), Inc. The merged company will be named SDT Holdings, Inc. and will provide filings and disclosures. The merger aims to access international markets and growth capital.